SCHEMBL271817

SCHEMBL271817

O=c1nc[nH]c2c1sc1ncccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIMK1 P53667 3/20 0.41
CLK1 P49759 2/20 0.41
CDC7 O00311 1/20 0.41
DBF4 Q9UBU7 1/20 0.41
LMNA P02545 2/20 0.38
RAB9A P51151 2/20 0.38
NPC1 O15118 1/20 0.38
TSHR P16473 1/20 0.38
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
IKBKB O14920 1/20 0.38
CHUK O15111 1/20 0.38
ALDH1A1 P00352 3/20 0.36
HPGD P15428 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
RXFP1 Q9HBX9 2/20 0.35
KAT2B Q92831 1/20 0.35
PARP1 P09874 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2300776 0.76 ALDH1A1 (0.34) CDC7RAB9ATSHRIKBKBALDH1A1
SCHEMBL2299934 0.75 LIMK1 (0.42) LIMK1CLK1CDC7PDE4APDE4B
SCHEMBL2303335 0.75 CYP1A2 (0.32) LMNARAB9AALDH1A1HPGD
SCHEMBL278692 0.75 CDC7 (0.51) LIMK1CLK1CDC7DBF4LMNA
SCHEMBL5729400 0.72 KDM4E (0.46) LIMK1CLK1CDC7DBF4LMNA
SCHEMBL2303768 0.71 KDM4A (0.41) LIMK1ALDH1A1PARP1
SCHEMBL2302794 0.71 KDM4A (0.44) LIMK1ALDH1A1HPGDPARP1PDPK1
SCHEMBL14780491 0.70 LIMK1 (0.53) LIMK1CLK1CDC7DBF4IKBKB
SCHEMBL3084745 0.67 AXL (0.53) SMN1; SMN2PARP1PDPK1CA12ALOX15
SCHEMBL10309423 0.67 LIMK1 (0.45) LIMK1CLK1CDC7DBF4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116209775-A Detection of methylation status 潘塔贝斯公司 2023-06-02 CN claimed
EP-4172361-A1 DETECTION OF METHYLATION STATUS Pentabase APS (DK) 2023-05-03 EP claimed
US-10988810-B2 Methods and materials for detection of mutations PENTABASE APS (DK) 2021-04-27 US claimed
US-20190085400-A1 METHODS AND MATERIALS FOR DETECTION OF MUTATIONS PENTABASE APS (DK) 2019-03-21 US claimed
EP-2004847-A2 OLIGONUCLEOTIDES COMPRISING SIGNALLING PAIRS AND HYDROPHOBIC NUCLEOTIDES, STEMLESS BEACONS, FOR DETECTION OF NUCLEIC ACIDS, METHYLATION STATUS AND MUTANTS OF NUCLEIC ACIDS Pentabase Aps (DK) 2008-12-24 EP claimed
WO-2007104318-A2 OLIGONUCLEOTIDES COMPRISING SIGNALLING PAIRS AND HYDROPHOBIC NUCLEOTIDES, STEMLESS BEACONS, FOR DETECTION OF NUCLEIC ACIDS, METHYLATION STATUS AND MUTANTS OF NUCLEIC ACIDS PENTABASE APS (DK) 2007-09-20 WO claimed
US-20250346955-A1 DETECTION OF METHYLATION STATUS PENTABASE APS (DK) 2025-11-13 US disclosed
EP-4172361-B1 DETECTION OF METHYLATION STATUS PENTABASE AS (DK) 2024-08-07 EP disclosed
CN-116209775-A Detection of methylation status 潘塔贝斯公司 2023-06-02 CN disclosed
EP-4172361-A1 DETECTION OF METHYLATION STATUS Pentabase APS (DK) 2023-05-03 EP disclosed
US-20220205024-A1 MELTING TEMPERATURE METHODS, KITS AND REPORTER OLIGO FOR DETECTING VARIANT NUCLEIC ACIDS PENTABASE APS (DK) 2022-06-30 US disclosed
CN-114286865-A Melting temperature methods, kits and reporter oligonucleotides for detecting variant nucleic acids 潘塔贝斯公司 2022-04-05 CN disclosed
EP-3969614-A1 MELTING TEMPERATURE METHODS, KITS AND REPORTER OLIGO FOR DETECTING VARIANT NUCLEIC ACIDS PentaBase ApS (DK) 2022-03-23 EP disclosed
US-20090192178-A1 mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS SCHERING CORPORATION 2009-07-30 US disclosed
US-20090082336-A1 mGluR1 Antagonists as Therapeutic Agents SCHERING CORPORATION 2009-03-26 US disclosed
US-7485648-B2 mGluR1 antagonists as therapeutic agents SCHERING CORPORATION (US) 2009-02-03 US disclosed
EP-2004847-A2 OLIGONUCLEOTIDES COMPRISING SIGNALLING PAIRS AND HYDROPHOBIC NUCLEOTIDES, STEMLESS BEACONS, FOR DETECTION OF NUCLEIC ACIDS, METHYLATION STATUS AND MUTANTS OF NUCLEIC ACIDS Pentabase Aps (DK) 2008-12-24 EP disclosed
WO-2007104318-A2 OLIGONUCLEOTIDES COMPRISING SIGNALLING PAIRS AND HYDROPHOBIC NUCLEOTIDES, STEMLESS BEACONS, FOR DETECTION OF NUCLEIC ACIDS, METHYLATION STATUS AND MUTANTS OF NUCLEIC ACIDS PENTABASE APS (DK) 2007-09-20 WO disclosed
US-20060167029-A1 mGluR1 Antagonists as therapeutic agents SCHERING CORPORATION 2006-07-27 US disclosed
US-20060009477-A1 mGluR1 antagonists as therapeutic agents SCHERING CORPORATION 2006-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192178-A1 mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS GRM1, GRM4, GRIA1 LIMK1 3031/4885CLK1 3660/4885CDC7 4254/4885
US-20060167029-A1 mGluR1 Antagonists as therapeutic agents GRM1, GRM4, GRIA1 LIMK1 3031/4885CLK1 3660/4885CDC7 4254/4885
US-20060009477-A1 mGluR1 antagonists as therapeutic agents GRM1, GRM4, GRIA1 LIMK1 2990/4885CLK1 3557/4885CDC7 4260/4885
US-20090082336-A1 mGluR1 Antagonists as Therapeutic Agents GRM1, GRM4, GRIA1 LIMK1 3031/4885CLK1 3660/4885CDC7 4254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.